Literature DB >> 32796312

Long-Term Outcomes of Zygomaticomaxillary Reconstruction With Autologous Bone Grafts Supported by Pedicled Buccal Fat Pad Flap.

Hanwen Chu1,2, Linjian Huang1, Feifei Xu1, Guanfu Chen1, Xin Xu1.   

Abstract

PURPOSE: The purpose of this study was to investigate the effectiveness of the pedicle buccal fat pad flap combined with autogenous bone grafts to reconstruct zygomaticomaxillary defects after tumor resection.
MATERIALS AND METHODS: A retrospective case series analysis of 11 patients that underwent zygomaticomaxillary reconstruction after tumor resection with autologous bone grafts supported by pedicle buccal fat pad flap as the lining of the maxillary sinus from January 2009 to December 2015 was performed. All the patients underwent computed tomography to measure the aesthetic appearance, bone graft formation, mucosa of the maxillary sinus, and their response to treatment, including complications.
RESULTS: With a mean follow-up period of 4.7 years, all patients were pleased with the symmetrical contours of zygomaticomaxillary and symptom improvements of the maxillary sinus except for one patient who complained of transient infraorbital numbness. Recurrence, bone infection or necrosis, and other complications were not observed in the follow-up period.
CONCLUSION: Pedicled buccal fat pad flap promotes wound healing and prevents the exposure of bone grafts to the maxillary sinus. This technique may be a promising treatment option when reconstructing complicated zygomaticomaxillary defects.
Copyright © 2020 by Mutaz B. Habal, MD.

Entities:  

Mesh:

Year:  2021        PMID: 32796312     DOI: 10.1097/SCS.0000000000006842

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  1 in total

1.  Use of buccal fat pad-derived stem cells cultured on bioceramics for repair of critical-sized mandibular defects in healthy and osteoporotic rats.

Authors:  Fabio Camacho-Alonso; M R Tudela-Mulero; J A Navarro; A J Buendía; A M Mercado-Díaz
Journal:  Clin Oral Investig       Date:  2022-05-07       Impact factor: 3.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.